Who is sponsoring NCT05934084?

NCT05934084 is sponsored by Fondazione Italiana Linfomi - ETS.

What condition does NCT05934084 study?

NCT05934084 studies Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL).

Is NCT05934084 still recruiting?

NCT05934084 is currently recruiting now. Last updated 12 January 2026.

Last reviewed 2026-01-12 · How we verify

NCT05934084

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Recruiting now NA Last updated 12 January 2026

What this trial tests

NA trial testing Lifestyles Implemented-Survivorship Care Plan (LS-SCP) in Classical Hodgkin Lymphoma in 552 participants. Currently enrolling.

Timeline

26 February 2024

Primary endpoint
1 February 2026

1 February 2026

Quick facts

Lead sponsor	Fondazione Italiana Linfomi - ETS
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	552
Start date	26 February 2024
Primary completion	1 February 2026
Estimated completion	1 February 2026
Sites	40 locations across Italy

Drugs / interventions tested

Lifestyles Implemented-Survivorship Care Plan (LS-SCP)

Conditions studied

Classical Hodgkin Lymphoma — all drugs for Classical Hodgkin Lymphoma →
Diffuse Large B Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B Cell Lymphoma (DLBCL) →
Primary Mediastinal Large B-cell Lymphoma (PMBCL) — all drugs for Primary Mediastinal Large B-cell Lymphoma (PMBCL) →

Sponsor

Fondazione Italiana Linfomi - ETS — full company profile →

Who can join

Adults 18 to 50, any sex, with Classical Hodgkin Lymphoma or Diffuse Large B Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Publication Only
· 2025

Verify or expand the search:

Other recruiting trials for Classical Hodgkin Lymphoma

Currently open trials in the same condition.

NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
NCT06848569 — Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study · Phase 2 · recruiting
NCT06563245 — Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment · Phase 2, PHASE3 · recruiting
NCT05900765 — A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma · Phase 2 · recruiting
NCT05404945 — Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above · Phase 2 · recruiting

Other Fondazione Italiana Linfomi - ETS trials

Trials by the same sponsor.

NCT07453095 — Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy · Phase 2 · not yet recruiting
NCT07256158 — PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma · Phase 3 · not yet recruiting
NCT07207785 — PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma · Phase 2 · not yet recruiting
NCT06781359 — Study on Plasmablastic Lymphoma Patients · recruiting
NCT06492837 — Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05934084 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Italiana Linfomi - ETS
Last refreshed: 12 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05934084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing